Buy SS-31 Online
SS-31, also known as Elamipretide or MTP-131, is a mitochondria-targeted synthetic tetrapeptide designed to interact with cardiolipin within the inner mitochondrial membrane.
It has progressed into substantial human clinical research involving mitochondrial disorders, cardiovascular conditions, and age-related mitochondrial dysfunction.
Product Information
Elamipretide is designed to selectively accumulate within mitochondria and interact with cardiolipin. This makes it different from peptides that act primarily through receptors on the cell surface.
Research has focused on mitochondrial energy production, membrane stability, oxidative stress, and cellular bioenergetics.
How Does SS-31 Work?
SS-31 binds to cardiolipin in the inner mitochondrial membrane, helping stabilize mitochondrial structure and supporting efficient mitochondrial energy production.
SS-31 Benefits
Supports Mitochondrial Function:
Elamipretide has been developed specifically to target mitochondrial dysfunction. Research has shown effects on mitochondrial membrane organization and cellular energy production.
Supports Oxidative-Stress Research:
By interacting with cardiolipin, SS-31 may help preserve mitochondrial membrane integrity during oxidative stress. This has made it an important research candidate in diseases involving impaired mitochondrial function.
Research Into Muscle and Cardiovascular Function:
Human studies have evaluated Elamipretide in mitochondrial myopathy and cardiovascular conditions. Its effects on mitochondrial bioenergetics make it particularly relevant to research involving skeletal and cardiac muscle.
SS-31 Side Effects
Clinical studies have commonly reported injection-site reactions. Headache, nausea, dizziness, fatigue, and other adverse events have also been reported depending on the study population and dosing protocol.
SS-31 Dosage
Clinical research has evaluated several dosing approaches. One mitochondrial myopathy trial studied intravenous Elamipretide at 0.01, 0.1, and 0.25 mg/kg/hour for 2 hours. Other trials have evaluated 40 mg subcutaneously once daily.
These doses belong to specific clinical research protocols and vary according to indication and route.
Research References
Karaa A, Haas R, Goldstein A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90:e1212–e1221. PMID: 29500292.
PubMed
Ehlers JP, et al. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration. Ophthalmology Science. 2024. PMID: 39605874.
PubMed
Purerawz Disclaimer
Purerawz does not sell, manufacture, stock, dispense, or directly supply any of the products discussed on this website. Purerawz is an affiliate-information website and may provide affiliate links to independent third-party suppliers.
The information provided in these pages is intended for educational and informational purposes only and should not be considered medical advice, diagnosis, or a recommendation to use any peptide. Research doses are included to describe published study protocols and are not individualized dosing instructions. Product quality, formulation, purity, route of administration, regulatory status, and availability may vary between suppliers and jurisdictions.
